Lightnews — Scholar-powered news

Maurizio Callari @mauriziocallari.bsky.social · Jun 18

Having a great time at #EACR2025, catching up and continuing doing exciting science with @carloscaldas1960.bsky.social and @caldaslab.bsky.social!

Carlos Caldas 🇵🇹🇮🇱🇪🇺🇬🇧🎗 @carloscaldas1960.bsky.social · Jun 17

snDNAseq of 40,000 cells from 140 tumors from #METABRIC. @mauriziocallari.bsky.social and @sc10021.bsky.social will soon write a major papers from this work! @caldaslab.bsky.social continues to produce outstanding science!

1 5

Reposted by Maurizio Callari

Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · May 19

Afami-cel showed durable responses in heavily pretreated patients with sarcoma, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy
fondazionebonadonna.org/en/afamitres...
#fondazionebonadonna #oncology #CancerResearch
@mauriziocallari.bsky.social

Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma

Fondazione Gianni Bonadonna

fondazionebonadonna.org

1 1

Reposted by Maurizio Callari

Long V. Nguyen @nguyenlab.bsky.social · May 12

I am excited to share the latest publication from the Nguyen, Caldas @carloscaldas1960.bsky.social and Rueda labs @ruedalab.bsky.social. This was a massive effort from a fantastic team and I’m grateful to everyone on the paper for their work on this project! doi.org/10.1016/j.ce...
#bcsm #PDTX

Redirecting

doi.org

3 6 14

Reposted by Maurizio Callari

Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · May 7

Whole genome sequencing-powered ctDNA sequencing improves detection at baseline and follow-up helping to identify early breast cancer patients at high risk of relapse
www.fondazionemichelangelo.org/news-update/...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

An ultrasensitive ctDNA detection platform is highly prognostic in early breast cancer - Fondazione Michelangelo

Whole genome sequencing-powered ctDNA sequencing improves detection at baseline and follow-up, helping to identify early breast cancer patients at high risk of relapse

www.fondazionemichelangelo.org

1 1

Reposted by Maurizio Callari

Carlos Caldas 🇵🇹🇮🇱🇪🇺🇬🇧🎗 @carloscaldas1960.bsky.social · Apr 16

1/n
Fantastic to see this published. Anticipatory genomics demonstration: ctDNA and ML to predict CT progression!
Well done @emmajb001.bsky.social and @mortegaduran.bsky.social! Great collaboration of @caldaslab.bsky.social with @ruedalab.bsky.social!
#DETECT started by @sj-dawson.bsky.social!

Oscar M Rueda @ruedalab.bsky.social · Apr 16

Excited to share our latest work on monitoring response to treatment using ctDNA and shallow WGS using a Bayesian Model developed by Solon Karapanagiotis with @Carloscaldas1960.bsky.social, Emma Beddowes and @mortegaduran.bsky.social

febs.onlinelibrary.wiley.com/doi/full/10....

1 5 6

Maurizio Callari @mauriziocallari.bsky.social · Mar 10

Here an overview of our #translational research on samples from the #NAPHER2 trial recently published in #NatComms @natureportfolio.nature.com. We identified #predictive #biomarkers and molecular dynamics in HER2+ER+ #breastcancer receiving chemo-free #targeted #treatment 👇

Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Mar 10

Analysis of molecular data from the NA-PHER2 trial, led from Michelangelo researchers identified new biomarkers predictive of response in HER2+/ER+ breast cancer patients receiving targeted treatments
www.fondazionemichelangelo.org/2025/03/10/n...

New insights into the drivers and dynamics of HER2+/ER+ breast cancer response to targeted treatments - Fondazione Michelangelo

Analysis of molecular data from the NA-PHER2 trial, led by Fondazione Michelangelo researchers, identified new biomarkers predictive of response in HER2+/ER+ breast cancer patients receiving targeted ...

www.fondazionemichelangelo.org

2

Maurizio Callari @mauriziocallari.bsky.social · Mar 9

Thank you for your words! And feel free to reach out for more info

1 1

Maurizio Callari @mauriziocallari.bsky.social · Mar 5

Thank you to all co-authors: Matteo dugo, Marco Barreca, Giampaolo Bianchini, Luca Gianni et al, funding, #AIRC, #BCRF, fondazionemichelangelo.org @fgbonadonna.bsky.social and all patients!

1

Maurizio Callari @mauriziocallari.bsky.social · Mar 5

Recent findings from the #PATINA trial further confirmed the efficacy of combined targeted treatment in HER2+ER+ BC. We provide a better understanding of #drivers and #dynamics of HER2+ER+ tumour response, towards to the design of de-escalation or #escalation strategies.

1 1

Maurizio Callari @mauriziocallari.bsky.social · Mar 5

The HighHigh group showed #dysfunctional immune infiltration and overexpression of #therapeutic #targets like #PAK4 at baseline. The LowLow group exhibited a #LuminalA phenotype by the end of treatment

1

Maurizio Callari @mauriziocallari.bsky.social · Mar 5

Stratification based on Ki67 at Day14 and at surgery defined three response groups (Ki67 HighHigh, LowHigh, LowLow), with divergent tumour and stroma expression dynamics

1

Maurizio Callari @mauriziocallari.bsky.social · Mar 5

We performed #RNAseq and #TIL assessment in serial biopsies from the NA-PHER2 trial. High #immune #infiltration and low #ER signalling at baseline correlated with #pCR, while #TP53 mutations associated with high Day14 #Ki67

1

Maurizio Callari @mauriziocallari.bsky.social · Mar 5

HER2+ER+ BC shows lower response to chemo+antiHER2 treatment. #Biomarker-guided alternative approaches could improve #outcomes and reduce #toxicities.
#NAPHER2 trial investigated #neoadjuvant #HER2 blockade and CDK4/6 inhibition with or without #endocrine therapy in HER2+ER+ BC.

1 1

Maurizio Callari @mauriziocallari.bsky.social · Mar 5

📢 Our work just published in
@naturecomms.bsky.social @natureportfolio.nature.com!
What is driving #response to #targeted #treatments in HER2+ER+ #breastcancer? How is the tumour ecosystem affected by treatment? Find the answers in our paper 👉 rdcu.be/ecbVR
Key points below 👇

Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies

Nature Communications - NA-PHER2 was a neoadjuvant trial of HER2-targeted trastuzumab and pertuzumab plus the CDK4/6 inhibitor palbociclib with or without endocrine therapy in HER2-positive,...

rdcu.be

2 5 16

Reposted by Maurizio Callari

Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Mar 3

Nivolumab plus ipilimumab show superior progression-free survival versus nivolumab in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
fondazionebonadonna.org/en/nivolumab...
#fondazionebonadonna #oncology #CancerResearch
@mauriziocallari.bsky.social

Nivolumab and ipilimumab in metastatic colorectal cancer

Fondazione Gianni Bonadonna

fondazionebonadonna.org

1 2

Reposted by Maurizio Callari

EACR - European Association for Cancer Research @helloeacr.bsky.social · Feb 19

Listen to episode 19 of The Cancer Researcher Podcast where @carloscaldas1960.bsky.social shares insights into his breast cancer research, the evolution of cancer science & the power of patient-derived xenograft models ahead of his Keynote Talk at EACR 2025.

magazine.eacr.org/insights-fro...

Insights from a Keynote Speaker: Episode 19 of The Cancer Researcher Podcast - The Cancer Researcher

Carlos Caldas shares insights into his breast cancer research and the power of patient-derived xenograft models.

magazine.eacr.org

1 5

Reposted by Maurizio Callari

Carlos Caldas 🇵🇹🇮🇱🇪🇺🇬🇧🎗 @carloscaldas1960.bsky.social · Feb 6

Just finished a Teams meeting with @mauriziocallari.bsky.social and Oscar Rueda discussing Single Nucleus Sequencing generated by @sc10021.bsky.social from 150 #METABRIC breast cancers, in conjunction with all the other multi-omic data. At #EACR2025 update coming...

2 6

Reposted by Maurizio Callari

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · Dec 5

#MedSky #OncSky #Altmetrics @cosmocollab.bsky.social @oncoalert.bsky.social

1 6

Maurizio Callari @mauriziocallari.bsky.social · Nov 29

Amazing resource for pre-clinical research in triple-negative breast cancer!

bioRxiv Cancer Bio @biorxiv-cancer.bsky.social · Nov 29

An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naive and longitudinal samples throughout neoadjuvant chemotherapy https://www.biorxiv.org/content/10.1101/2024.11.25.625287v1

Triple negative breast cancer (TNBC) that fails to respond to neoadjuvant chemotherapy (NACT) can be

www.biorxiv.org

1 3

Reposted by Maurizio Callari

Nuria Lopez-Bigas @nlbigas.bsky.social · Nov 25

We recently announced a dual new release of intOGen and boostDM

Computational analysis of 33,218 tumor genomes to identify cancer genes and driver mutations

➡️ Compendium of Cancer Driver Genes - www.intogen.org

➡️ In Silico Saturation Mutagenesis of Cancer Genes - www.intogen.org/boostdm

33 83

Maurizio Callari @mauriziocallari.bsky.social · Nov 21

A great piece of work, I'm happy to have contributed to during my time in Cambridge! #PDX #breastcancer #drug #response #prediction

Alejandra Bruna @alejandrapcelab.bsky.social · Nov 21

Our breast cancer PDX paper out in Cancer Research
Breast cancer PDXs can predict patient drug responses, and model phenotypic and functional cancer evolution.
Full text available: lnkd.in/eDNN_gpQ

Modeling Drug Responses and Evolutionary Dynamics using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple Negative Breast Cancer

Abstract. The inter- and intra-tumor heterogeneity of triple negative breast cancers (TNBC), which is reflected in diverse drug responses, interplays with tumor evolution. Here, we developed a preclin...

aacrjournals.org

1

Reposted by Maurizio Callari

Itai Yanai @itaiyanai.bsky.social · Nov 20

Out today in Nature: "The Human Cell Atlas"! In my News and Views, I compare the cell atlas to early naturalists creating an atlas of South America. Researchers mining this cell atlas can now make big discoveries, just as the next naturalists then discovered evolution.
www.nature.com/articles/d41...

3 62 220

Maurizio Callari @mauriziocallari.bsky.social · Nov 18

I strongly support this

Altmetric @altmetric.com · Nov 18

We strongly suggest that academic publishers and other platforms that host research rapidly implement a Share to Bluesky button for their articles. Here's how:

docs.bsky.app/docs/advance...

#AcademicSky #HigherEd #Altmetrics

Action Intent Links | Bluesky

Authors, websites, and apps can use action intent links to implement "Share on Bluesky" buttons, or similar in-app actions. Logged-in users will be directed to the corresponding action view in the Blu...

docs.bsky.app